Table 2.
Recent publications on relapsed or refractory pediatric patients with acute myeloid leukemia.
| Reference | Drugs | Response (No. of patients) |
|---|---|---|
| Niktoreh et al. 2019 [59] | Gemtuzumab ozogamicin±other chemotherapeutic agents | 51% (36/71) |
| Cooper et al. 2019 [60] | CPX-351 (a liposomal preparation of cytarabine and daunorubicin) | 81% (30/37) CR/CRp/CRi |
| van Eijkelenburg et al. 2018 [61] | Clofarabine, liposomal daunorubicin, high-dose cytarabine | 68% (21/31) CR/CRi/PR |
| Messinger et al. 2017 [62] | Clofarabine, cyclophosphamide, and etoposide | 51% (9/17) CR/CRp/CRi |
| Cooper et al. 2017 [63] | Plerixafor, high dose cytarabine, etoposide | 23% (3/13) CR/CRp/CRi |
| Horton et al. 2014 [64] | Bortezomib, low-dose cytarabine, idarubicin | 57.1% (8/14) CR/CRp/CRi (cycle 1) |
| Bortezomib, high-dose cytarabine, etoposide | 47.8% (11/23) CR/CRp/CRi (cycle 1) | |
| Cooper et al. 2014 [57] | Clofarabine, cytarabine | 45% (21/47) CR/CRp |
| Shukla et al. 2014 [56] | Clofarabine, topotecan, vinorelbine, thiotepa | 67% (8/12) |
| Kaspers et al. 2013 [55] | FLAG | 59% (117/197) |
| FLAG+liposomal daunorubicin | 69% (135/197) | |
| Miano et al. 2012 [58] | Clofarabine, etoposide, cyclophosphamide | 44% (7/16) CR/CRi |
| Inaba et al. 2011 [65] | Clofarabine, cytarabine, daily sorafenib | 72% (8/11) CR/CRi |
| Inaba et al. 2010 [66] | Cladribine, topotecan | 35% (9/26) |
Abbreviations: CR, complete remission; CRi, complete remission with incomplete count recovery; CRp, notable CR with incomplete platelet recovery; FLAG, fludarabine, high dose cytarabine, filgrastim.